11:16 AM EST, 12/03/2024 (MT Newswires) -- Lisata Therapeutics ( LSTA ) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.

Financial details weren't disclosed.

The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.

The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.

Price: 2.77, Change: +0.02, Percent Change: +0.65